Core Insights - Aptiv PLC is expected to release its first-quarter 2025 results on May 1, with consensus estimates for earnings per share (EPS) at $1.55 and revenues at $4.78 billion, indicating a 33.62% growth in EPS year-over-year [1][2] Financial Performance - The Zacks Consensus Estimate for Aptiv's quarterly revenues suggests a year-over-year decline of 2.40%, despite the company beating earnings estimates in the last four quarters with an average surprise of 9.88% [2] - In Q4 2024, Aptiv reported an adjusted EPS of $1.75, surpassing the Zacks Consensus Estimate of $1.66, and net sales of $4.91 billion, exceeding the estimate of $4.88 billion, with the top line remaining flat year-over-year [2] Revenue Projections - For full-year 2025, Aptiv projects revenues between $19.6 billion and $20.4 billion, reflecting a 2% year-over-year increase at the midpoint, driven by mid-single-digit growth in the AS&UX business and low-single-digit growth in the ECG business [3] Cost Management and Margins - The advanced safety and user experience segment is benefiting from cost reductions by shifting AI workloads to the edge, contributing to improved margins [4] - For 2025, Aptiv expects an adjusted EBITDA margin in the range of 15.8% to 16.1%, compared to 15.7% reported in 2024 [5] Earnings Expectations - Aptiv has a positive Earnings ESP of +3.50%, indicating a likelihood of an earnings beat for the upcoming quarter, supported by a Zacks Rank of 3 [6][7]

Core Viewpoint - Revvity, Inc. (RVTY) is expected to report its first-quarter 2025 results on April 28, with a consensus estimate for revenues at $662.2 million, reflecting a 1.9% increase year-over-year, while earnings per share (EPS) is projected at 96 cents, indicating a 2% decline year-over-year [1][2]. Q1 Estimates - The Zacks Consensus Estimate for revenues is $662.2 million, up 1.9% from the prior-year quarter [1] - The consensus mark for earnings is 96 cents per share, indicating a deterioration of 2% year-over-year [1] - Organic top-line growth is expected to be 3-5% in Q1, with 19% of full-year adjusted EPS guidance of $4.90-$5.00 anticipated in this quarter [2] Diagnostics Segment - The Diagnostics segment sales improved 6% organically in the fourth quarter, with strong performance expected to continue in Q1, driven by growth in Immunodiagnostics and Reproductive Health [3] - Immunodiagnostics is projected to grow in high-single digits, supported by strong commercial execution [3] - The estimated revenue for the Diagnostics segment is $324.8 million, down 6.4% year-over-year [6] Life Sciences Segment - The Life Sciences business improved 5% organically in the last reported quarter, primarily driven by recovery in pharma/biotech customer activity [7] - The estimated revenue for the Life Sciences segment is $338 million, up 11.6% year-over-year [8] - New offerings, Signals Clinical and Signals Synergy, are likely to drive adoption of Signals software during Q1 [7] Other Factors to Consider - Revvity announced an expansion of its work with Genomics England to advance genomic initiatives, which may boost newborn screening [9] - The launch of the TotalSeq Phenocyte single-cell protein profiling solution in collaboration with Scale Biosciences may have contributed additional revenues for the Life Sciences segment [10] - The company generates a portion of its sales from China, which is a crucial growth factor for its business in Asia [11] Earnings Beat Likely - The model predicts an earnings beat for Revvity, with an Earnings ESP of +0.52% [12]

Arch Capital Group Ltd. (ACGL) is expected to register an improvement in its top line but a decline in its bottom line when it reports first-quarter 2025 results on April 29, after the closing bell.The Zacks Consensus Estimate for BRO’s first-quarter revenues is pegged at $4.55 billion, indicating 20.7% growth from the year-ago reported figure.The consensus estimate for earnings is pegged at $1.37 per share. The Zacks Consensus Estimate for ACGL’s first-quarter earnings has moved down 6.2% in the past 30 da ...

Comstock Resources, Inc. (CRK) is set to report first-quarter earnings on April 30, after the closing bell.Let us analyze the factors that are expected to have influenced CRK’s performance in the first quarter of 2025. Before that, it is worth taking a look at the company’s performance in the last reported quarter.Highlights of Q4 EarningsIn the last reported quarter, the exploration and production company’s earnings surpassed the consensus mark. CRK reported an adjusted earnings of 16 cents per share, whic ...

Hospital operator Universal Health Services, Inc. (UHS) is set to report first-quarter 2025 results on April 28, 2025, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $4.36 per shareon revenues of $4.14 billion. (See the Zacks Earnings Calendar to stay ahead of market-making news.)The first-quarter earnings estimate witnessed five upward revisions over the past 60 days, against no movement in the opposite direction. The bottom-line projec ...

Biogen (BIIB) will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's earnings beat expectations by 0.58%. The Zacks Consensus Estimate for first-quarter sales and earnings is pegged at $2.24 billion and $3.34 per share, respectively. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)Factors to Consider for BiogenIn the first quarter, lower sales of multiple sclerosis (“MS”) drugs are likely to have been offset by revenues ...

Core Viewpoint - C.H. Robinson (CHRW) is expected to report first-quarter 2025 results on April 30, with earnings per share estimated at $1.02, reflecting an 18.6% increase year-over-year, despite a 3.8% downward revision in estimates over the past 60 days [1][2]. Financial Estimates - The Zacks Consensus Estimate for revenues is projected at $4.3 billion, indicating a 2.2% decrease from first-quarter 2024 actuals [1]. - Revenue estimates for the transportation segment are pegged at $4.1 billion, slightly down from the previous year [3]. - North American Surface Transportation revenues are estimated at $3 billion, a 0.7% decline from the year-ago figure [4]. - Global Forwarding segment revenues are anticipated to be $906.4 million, representing a 23.3% increase year-over-year [4]. Operational Insights - CHRW's operational efficiency, driven by cost-cutting initiatives, is expected to positively impact bottom-line performance [5]. - The company has a strong earnings history, surpassing the Zacks Consensus Estimate in the last four quarters with an average beat of 21.7% [2]. Earnings Prediction Model - The current model does not predict an earnings beat for CHRW, as it has an Earnings ESP of +1.36% and a Zacks Rank of 4 (Sell) [6].

Core Viewpoint - Elevance Health, Inc. reported strong first-quarter 2025 results with adjusted EPS of $11.97, exceeding estimates and showing a year-over-year increase of 10.5% [1][2] Financial Performance - Operating revenues reached $48.8 billion, a 15.4% increase year over year, surpassing consensus estimates by 6% [1][4] - Premiums rose 14.5% year over year to $40.9 billion, exceeding the consensus mark of $38.7 billion [4] - Product revenues increased by 29.1% year over year to $5.8 billion, also beating estimates [4] - Net investment income grew 26.9% year over year to $590 million, surpassing the consensus of $461.3 million [4] - Total expenses were $46.1 billion, up 16.3% year over year, higher than estimates due to increased benefit expenses and operating costs [5] Membership and Operational Update - Medical membership stood at approximately 45.8 million, a 0.5% decline year over year, attributed to Medicaid attrition [3] - The reported membership figure fell short of the Zacks Consensus Estimate of 46.2 million [3] Segment Performance - Health Benefits segment revenues totaled $41.4 billion, an 11.2% year-over-year increase, beating estimates [6] - Carelon segment revenues reached $16.7 billion, a 38% increase year over year, driven by acquisitions and product revenue growth [7] - Corporate & Other segment reported revenues of $165 million with an operating loss of $140 million, wider than the previous year's loss [9] Financial Position - Cash and cash equivalents were $7.5 billion, down from $8.3 billion at the end of 2024 [10] - Total assets increased to $119.7 billion from $116.9 billion at the end of 2024 [10] - Long-term debt decreased to $28.1 billion from $29.2 billion [11] - Total equity grew to $42.6 billion from $41.4 billion at the end of 2024 [11] Capital Deployment - The company repurchased shares worth $880 million in Q1 2025, with $8.4 billion remaining under its buyback authorization [12] - A quarterly dividend of $1.71 per share was paid, totaling $386 million [12] 2025 Outlook - The company reaffirmed adjusted EPS guidance between $34.15 and $34.85, an increase from the 2024 figure of $33.04 [13] - Operating revenues are expected to grow in the high-single to low-double digits from $175.2 billion in 2024 [15] - Medical enrollment is forecasted to be between 45.8 and 46.7 million in 2025 [15]

Core Viewpoint - Xcel Energy (XEL) is expected to report its first-quarter 2025 results on April 24, with a prior negative earnings surprise of 6.9% in the last quarter [1] Factors Impacting Q1 Earnings - The company is adding new electric and natural gas customers, which is likely to positively impact performance in the upcoming quarter [2] - Demand from data centers, electric vehicle adoption, and economic growth in the service region are expected to benefit quarterly earnings [3] - Increased operation and maintenance expenses may offset some positive factors, with severe windstorms in Texas and New Mexico potentially negatively impacting earnings [3] Earnings Estimates - The Zacks Consensus Estimate for earnings is 96 cents per share, reflecting a year-over-year increase of 9.09% [4] - The consensus revenue estimate is $3.93 billion, indicating a year-over-year improvement of 7.82% [4] Earnings Prediction Model - The current model does not predict an earnings beat for Xcel Energy, with an Earnings ESP of -2.08% and a Zacks Rank of 4 (Sell) [5][6]

Core Insights - Discover Financial Services (DFS) is expected to report its Q1 2025 results on April 23, with earnings estimated at $3.32 per share and revenues at $4.21 billion, indicating a year-over-year earnings increase of 201.8% [1] - The current year revenue estimate for DFS is $17.32 billion, reflecting a 3.6% decline year-over-year, while the EPS estimate is $13.79, suggesting a 22.2% decrease [2] - DFS has beaten earnings estimates in three of the last four quarters, with an average surprise of 27.2% [2] Earnings Predictions - The model predicts an earnings beat for DFS, supported by a positive Earnings ESP of +2.53% and a Zacks Rank of 3 (Hold) [3] - Revenue growth in Q1 is expected to be driven by PULSE Network volume, with an estimated growth of 8.4% year-over-year, while the Zacks Consensus Estimate for PULSE Network stands at $85.7 billion [4] - Non-interest income is estimated at $691.6 million, marking a 2.8% year-over-year increase, with expectations of total operating expenses rising by 15.2% due to increased compensation and benefits [5][6]